BCB

BrainChild Bio is a private, clinical-stage biotechnology company developing CAR-T cell therapies for tumors in the central nervous system, with an initial focus on pediatric brain cancers. The company was launched out of Seattle Children’s and is advancing autologous, locoregionally delivered CAR-T therapies designed to overcome challenges of treating CNS tumors. Its lead program, BCB-276, is a B7-H3-targeting CAR-T therapy for diffuse intrinsic pontine glioma in children and young adults, and the company has disclosed plans for a pivotal Phase 2 registrational study intended to support a future BLA. Beyond DIPG, BrainChild Bio is extending its platform toward additional pediatric and adult CNS tumors, including glioblastoma and brain metastases. The company emphasizes repeated intracerebroventricular dosing and multiplexed targeting approaches to improve tumor access, persistence, safety, and efficacy in brain tumors.